Purging marrow or peripheral blood stem cells for autografting

Current Opinion in Hematology

Volumn 4, Issue 6, 1997, Pages 423-428

  Hammert, Lisa C ^a   Ball, Edward D ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTISENSE OLIGONUCLEOTIDE; CD34 ANTIGEN; CYTARABINE; GENISTEIN; MONOCLONAL ANTIBODY; PHTHALIC ACID; PROTEIN TYROSINE KINASE INHIBITOR;

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; CANCER RECURRENCE; CANCER SURVIVAL; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MINIMAL RESIDUAL DISEASE; MORBIDITY; MORTALITY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL; TUMOR CELL;

EID: 0030862188     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704060-00011     Document Type: Short Survey

References (51)

1. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, et al.: Genetic marking shows that PH+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994, 83:3068-3076.
2. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro JJ, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993, 341:85-86.
3. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994, 84:380-383.
4. Sharkis SJ, Santos GW, Colvin M: Elimination of acute myelogenous leukemia cells from bone marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide. Blood 1980, 55:521-523.
5. Sieber F, Spivak JL, Sutcliffe AM: Elective killing of leukemia cells by merocyanine 540-mediated photosensitization. Proc Natl Acad Sci U S A 1984, 81:7584-7587.
6. Ball ED, Mills LE, Cornwell GG, Davis BH, Coughlin CT, Howell AL, Stukel TA, Dain BJ, McMillan R, Spruce W: Autologous bone marrow transplantation for acute myeloid leukemia using monoclonal antibody-purged bone marrow. Blood 1990, 75:1199-1206.
7. Ball ED, Mills LE, Coughlin CT, Beck JR, Cornwell GG: Autologous bone marrow transplantation in acute myelogenous leukemia: In vitro treatment with myeloid cell-specific monoclonal antibodies. Blood 1986, 68:1311-1315.
8. DeFabritiis P, Ferrero D, Sandrelli A, Tarella C, Meloni G, Pulsoni A, Pregno P, Badoni R, DeFelice L, Gallo E, Amadori S, Mandelli F, Pileri A: Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission. Bone Marrow Transpl 1989, 4:669-674.
9. Robertson MJ, Soiffer RJ, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ, Murray C, Dear K, Griffin JD, Nadler LM, Ritz J: Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 1992, 79:2229-2236.
10. Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK, Braine HG, Burke PJ, Ambinder RF, Burns WH, et al.: Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia using ex vivo marrow treatment with 4-hydroperoxcyclophosphamide. N Engl J Med 1986, 315:141-147.
11. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D, et al.: Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 1990, 75:1606-1614.
12. Miller CB, Rowlings PA, Jones RJ, Keating A, Zhang MJ, Horowitz MM: Autotransplants for acute myelogenous leukemia (AML): Effect of purging with 4-hydroperoxcyclophosphamide (4 HC). Proc Am Soc Clin Oncol 1996, 15:338.
13. Stein AS, O'Donnell MR, Chai A, Schmidt GM, Nademanee A, Parker PM, Smith EP, Snyder DS, Molina A, Stepan DE, et al.: In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol 1996, 14:2206-2216. A prospective study that elucidates the efficacy of using a single course of high-dose cytarabine consolidative therapy as an in vivo purging method in 60 adult patients with acute myelogenous leukemia in first complete remission prior to marrow collection in preparation for autologous transplantation. Forty-four patients were evaluable. The results demonstrated an increased disease-free survival rate in these patients, comparable to that achieved with allogeneic transplantation.
14. Ngan BY, Nourse J, Cleary ML: Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 1989, 73:1759-1762.
15. Negrin RS, Blume KGI: The use of the polymerase chain reaction for the detection of minimal residual malignant disease. Blood 1991, 78:255-258.
16. Douay L, Hu C, Giarratana M-C, Gorin N-C: Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. Eur J Cancer 1995, 31A(Suppl 1):S14-S16.
17. Wang L, Chutse W, Xuetao P, Li X, Jurong C, Huihua X, Ke Y, Aiping T, Shuquan J: Dibutyl phthalate purged autologous bone marrow transplant in the treatment of leukemia. Leuk Res 1996, 20:343-348. Reports promising clinical results utilizing di-N-butyl phthalate as an in vitro purging agent in 14 patients with acute myelogenous leukemia in first complete remission who underwent autologous bone marrow transplantation. The preliminary data suggest that this agent is safe and effective in this setting and warrants further study in clinical trials.
18. Carlo-Stella C, Regazzi E, Garau D, Mangoni L, Rizzo MT, Bonati A, Dotti G, Almici C, Rizzoli V: Effect of the protein tyrosine kinase inhibitor Genistein on normal and leukaemic haemopoietic progenitor cells. Br J Haematol 1996, 93:551-557. Demonstrates the inhibitory growth activity of genistein on leukemic progenitors as compared with normal hematopoietic progenitor cells supporting its potential applicability as a marrow-purging agent, which warrants further investigation in clinical trials.
19. Neckers L, Whitesell L, Rosolen A, Geselowitz DA: Antisense inhibition of oncogene expression. Crit Rev Oncol 1992, 3:175-231.
20. Pierga JY, Magdelenat H: Applications of antisense oligonucleotides in oncology. Cell Mol Biol 1994, 40:237-261.
21. Pilowsky PM, Suzuki S, Minson JB: ANTISENSE oligonucloetides: a new tool in neuroscience. Clin Exp Pharmacol Physiol 1994, 21:935-944.
22. DeFabritiis P, Amadori S, Calabretta B, Mandelli F: Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transpl 1993, 12:261-265.
23. McManaway ME, Neckers LM, Loke SL, al-Nasser AA, Redner RL, Shiramizu BT, Goldschmidts WL, Huber BE, Bhatia K, Magrath IT: Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 1990, 335:808-811.
24. Gewirtz AM: Oligodeoxynucleotide-based therapeutics for human leukemias. Stem Cells 1993, 11(suppl 3):96-103.
25. Bergan R, Connell Y, Fahmy B, Neckers L: Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res 1993, 21:3567-3573.
26. Bayever E, Iversen PL, Bishop MR, Sharp JG, Tewary HK, Arneson MA, Pirruccello SJ, Ruddon RW, Kessinger A, Zon G, Armitage JO: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase I trial. Antisense Res Dev 1993, 3:383-390.
27. Bergan R, Hakim F, Schwartz GN, Kyle E, Cepada R, Szabo JM, Fowler D, Gress R, Neckers L: Electroporatlon of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood 1996, 88:731-741. Summarizes the results of using synthetic antisense oligodeoxynucleotides, introduced into cells by electroporation, as potential agents to suppress gene products (c-myc protein) associated with specific malignancies. The suppression of these targeted proteins resulted in cell death in different malignant cell lines in vitro. The data suggest that there may be clinical applicability for this method in bone marrow purging in vitro.
28. Cesano A, Pierson G, Visonneau S, Migliaccio AR, Santoli D: Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysissensitive or -resistant leukemic targets. Blood 1996, 87:393-403.
29. Cesano A, Santoli D: Two unique human leukemic T-cell lines endowed with a stable cytotoxic function and a different spectrum of target reactivity: analysis and modulation of their lytic mechanisms. In Vitro Cell Dev Biol 1992, 28A:64B-656.
30. Cesano A, Visonneau S, Santoli D: Treatment of experimental glioblastoma with a human MHC non-restricted cytotoxic T-cell line. Cancer Res 1995, 55:96-101.
31. Cesano A, O'Connor R, Lange B, Finan J, Rovera G, Santoli D: Homing and progression patterns of childhood acute lymphoblastic leukemia in severe combined immunodeficient mice. Blood 1991, 77:2463-2474.
32. Cesano A, Visonneau S, Cioe L, Clark SC, Santoli D: Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T-cell clone potentially useful In cancer therapy. Cancer Immunol Immunother 1995, 40:139-151.
33. Cesano A, Visonneau S, Cioe L, Clark SC, Rovera G, Santoli D: Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J Clin Invest 1994, 94:1076-1084.
34. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
35. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994, 330:100-106.
36. Zhong Rk, Donnenberg AD, Rubin J, Ball ED: Differential effect of 4-hydroperoxycyclophospamide and antimyeloid monoclonal antibodies on T and natural killer cells during bone marrow purging. Blood 1994, 83:2345-2351.
37. Condiotti R, Slavin S, Nagler A: Asta-Z 7557 impairs human natural killer (NK) cell activity. Leuk Res 1996, 20:169-174.
38. Almici C, Manoni L, Carlo-Stella C, Garau D, Cottafavi L, Rizzoli V: Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow. Bone Marrow Transpl 1995, 16:95-101.
39. Adler A, Chervenick PA, Whiteside TL, Lotzova E, Herberman RB: Interleukin-2 induction of lymphokine-activated killer (LAK) activity In the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation In adult patients with active disease and in remission. Blood 1988, 71:709-716.
40. Fefer A, Benyunes M, Higuchi C, York A, Massumoto C, Lindgren C, Buckner CD, Thompson JA: Interleukin-2 +/- lymphocytes as consolidative Immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Haematol 1993, 89(Suppl 1):2-7.
41. Scambia G, Panici PB, Pierelli L, Baiocchi G, Rumi C, Menichella G, Foddai ML, Serafini R, Arno E, Bonanno G, Bizzi B, Mancuso S: Immunological reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation for advanced ovarian cancer. Eur J Cancer 1993, 29:1518-1522.
42. van den Brink MRM, Voogt PJ, Marijt WAF, van Luxemburg-Heys SAP, van Rood JJ, Brand A: Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro. Blood 1989, 74:354-360.
43. Komatsu F, Kajiwara M: Usefulness of lymphokine-activated killer cells generated from bone marrow mononuclear cells for the purging of residual tumor cells in peripheral blood stem cell graft. Jpn J Cancer Res 1996, 87:161-169.
44. Nimgaonkar M, Kemp A, Lancia J, Ball ED: A combination of CD34 selection and complement-mediated immunopurging (anti-CD15 monoclonal antibody) eliminates tumor cells while sparing normal progenitor cells. J Hematotherapy 1996, 5:39-48.
45. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992, 80:879-886.
46. Rohatiner AZ, Johnson PW, Price CG, Arnott SJ, Amess JA, Norton AJ, Dorey E, Adams K, Whelan JS, Matthews J, et al.: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994, 12:1177-1184.
47. Gribben JG, Freedman AS, Woo SD, Blake K, Shu RS, Freeman G, Longtine JA, Pinkus GS, Nadler LM: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment Blood 1991, 78:3275-3280.
48. Lee MS, Chang KS, Cabanillas F, Freireich FJ, Trujillo JM, Stass S: Detection of minimal residual cells carrying the t(14:18) by DNA sequence amplification. Science 1987, 237:175-178.
49. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, et al.: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991, 325:1525-1533.
50. Johnson PW, Price CG, Smith T, Cotter FE, Meerabux J, Rohatiner AZ, Young BD, Lister TA: Detection of cells bearing the t(14:18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1994, 12:798-805.
51. Macintyre EA, Belanger C, Debert C, Canioni D, Turhan AG, Azagury M, Hermine O, Varet B, Flandrin G, Schmitt C: Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients. Blood 1995, 86:4691-4698.